Core Laboratories Inc.
CLB
$10.44
-$0.16-1.51%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.76% | -104.78% | 236.65% | 26.88% | -60.47% |
| Total Depreciation and Amortization | -2.65% | -3.28% | -5.42% | -6.44% | -4.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58.47% | -40.86% | -102.81% | -1,367.71% | 70.28% |
| Change in Net Operating Assets | -84.24% | 81.37% | 17.62% | 93.12% | 306.67% |
| Cash from Operations | -18.80% | 20.43% | 6.10% | 6,277.83% | 96.16% |
| Capital Expenditure | -51.01% | -17.27% | -60.12% | 21.15% | -31.83% |
| Sale of Property, Plant, and Equipment | 364.42% | 107.42% | 1,133.85% | 98.51% | -23.81% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 18.47% | 289.15% | -91.11% | 34,983.33% | -36.85% |
| Cash from Investing | -139.30% | 146.59% | -45.50% | 85.51% | -156.31% |
| Total Debt Issued | 50.00% | -7.14% | -50.00% | -79.75% | -90.80% |
| Total Debt Repaid | 42.86% | 11.76% | 25.93% | 71.08% | 75.29% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -1,590.74% | -4,495.45% | -174.89% | 10.09% | 18.59% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.21% | -0.21% | -0.43% | -0.43% | -0.43% |
| Other Financing Activities | 122.22% | 101.58% | 100.00% | 87.57% | 96.73% |
| Cash from Financing | 76.62% | -9.85% | -4.84% | -47.41% | -32,464.29% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 226.42% | 1,525.12% | -54.88% | 139.41% | -71.95% |